Recent Job Openings – Sept 2012

Here is a listing of recent pharma/device/biotech job openings in training, for those who are interested:

Manager, Sales Training and Development, Sunovion, MA

Sales Training Manager – Oncology, EMD Serono, MA

Manager/Associate Director, Oncology Clinical Training & Development, Novartis, NJ

Manager/Associate Director, Sales Training (Oncology), Novartis, NJ

Sales Training Manager, Shionogi, NJ

Hospital & Specialty Sales Trainer, Daiichi-Sankyo, NJ

National Sales Trainer, Daiichi-Sankyo, NJ

Director, Talent Management, Daiichi-Sankyo, NJ

Senior Manager, Leadership Development, Daiichi-Sankyo, NJ

Manager, Medical Device Training and Communications, Ikaria, NJ

Sales Training Manager – Oncology, Astellas, IL

Sr. Manager, Training & Communication (Compliance), Abbott, IL

Manager of Sales Training, Vivus, CA

Manager/Sr. Manager, Learning Technologies, Roche/Genentech, CA

Note: Impactiviti has no connection to the hiring personnel in these companies. The links are posted strictly as a service. Apply directly to the companies according to directions given on their individual job postings.

_________

Impactiviti is the Pharmaceutical Connection Agency. As the eHarmony of sales/training/marketing, we help our pharma/biotech clients find optimal outsource vendors through our unique trusted referral network. Need something? Ask Steve.

Learn more about us here.

 

Read Full Post »

Impactiviti Daily 061510 Top Pharma News

*****

TODAY’S NEWS:

Cheap drug could be a life-saver – A cheap drug that can stop bleeding in recently injured accident patients could potentially save the lives of tens of thousands worldwide, a new study says. Researchers studied the effects of tranexamic acid, or TXA, in more than 10,000 adult trauma patients in 40 countries who received the drug within 8 hours of being injured. They compared those patients’ outcomes to more than 10,000 accident victims who got a placebo treatment. The study was published online Tuesday in the medical journal Lancet…more

Pfizer ends development of one experimental RA drug from Trubion; keeps another one going.

Glaxo gets FDA OK for combo prostate treatment.

Human Genome Sciences: low expectations for Hepatitis C drug approval.

Judge to Abbott: Pay reps overtime.

RECOMMENDED

Social Media 101/201. Here at Impactiviti, we’re immersed in both social media and pharma. We’re happy to provide on-site workshops for our clients who need to bring sales/marketing/training/executive teams up to speed on Trends in Social Media.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for details.

PLUS

Fresh updates to the astonishingly helpful Dose of Digital Social Media (Pharma/Healthcare) Wiki. And, a little thought-provoking tidbit: The Red Pill or the Blue Pill?

JUST FOR FUN

Nature’s Patterns in Photography. Sheer eye candy.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

Impactiviti Daily 052110 Top Pharma News

*****

TODAY’S NEWS:

Abbott making a big India buy – The speculation that has been fuelling the shares of Piramal Healthcare over the past few days has been put to rest after Abbott Laboratories announced Friday that it will buy a unit of the Indian pharmaceutical company…more

Lots of Oncology. Rituxan: cutting lymphoma recurrence – The final phase of a drug study finds that two years of treatment with rituximab (Rituxan) cuts in half the risk that follicular lymphoma patients who respond to chemotherapy will suffer a recurrence of the disease…more And, some good news on sarcoma: An experimental drug from Ziopharm Oncology Inc. helped keep fast-growing sarcomas, lethal tumors that can grow to the size of basketballs, in check 77% longer than a standard treatment, a company-sponsored study found…more Plus, Amgen experimental drugs slow down some tumors.

Some side effects of popular cholesterol-lowering drugs? – Drugs to lower cholesterol and prevent heart disease, taken by millions of people worldwide, increase the risk of cataracts, kidney failure, muscle pain and liver dysfunction, a study of more than 2 million Britons found…more

RECOMMENDED

Social Media Community/Facebook Moderation and Management. Our social media partners offer a range of services, including community moderation and platform design. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

The Doctor Won’t See You Now training.

JUST FOR FUN

It’s spring, and the weather’s fine. So, go on one of America’s Scenic Drives.

AND, a pharma spoof – So, What’s your Problem with Gram-Negative Bacteria?

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

Impactiviti Daily 031010

*****

TODAY’S NEWS

Botox heading to an arm near you – The Food and Drug Administration said Tuesday it approved Allergan‘s botulinum-based drug Botox to treat spasms of the elbow, wrist and fingers…more

Abbott to boost pipeline with Facet buy – Abbott says the acquisition will boost its early- and mid-stage pharmaceutical pipeline. The developer has its eyes on two primary therapeutic areas–immunology and oncology. The highest-priority program is daclizumab, a Phase II biologic for multiple sclerosis that will move into Phase III trials in Q2 of 2010. Facet is already partnered with Biogen Idec on the compound. The biotech also has oncology compounds for multiple myeloma and chronic lymphocytic leukemia in early to mid-stage trials…more

FDA panel gives (preliminary) green light to InterMune’s lung drug.

Jury verdict against Novartis for rep who claimed retaliation after taking maternity leave.

RECOMMENDED

Curriculum Design – Sometimes you need a point solution – and sometimes you need a new strategic direction for your training curriculum. Not to worry – we’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

More docs using e-Prescribing. Look for this to keep accelerating.

JUST FOR FUN

Eye-catching examples of urban decay photography. More interesting than it sounds!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »